Antimicrobial peptides for leishmaniasis

Current Opinion in Investigational Drugs

Volumn 11, Issue 8, 2010, Pages 868-875

  Cobb, S L ^a   Denny, P W ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

AMP; antileishmanial; antimicrobial peptide; drug resistance; Leishmania; leishmaniasis; therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; BOMBININ; CA(1 8)M(1 18); CECROPIN A; DECORALIN; DEFENSIN; DERMASEPTIN; DERMASEPTIN S4; GOMESIN; HISTATIN 5; HYBRID PROTEIN; INDOLICIDIN; MAGAININ 2; MEGLUMINE ANTIMONATE; MELITTIN; MILTEFOSINE; OCT CA(1 7)M(2-9); PAROMOMYCIN; PENTAMIDINE; PHYLLOSEPTIN 1; POLYPEPTIDE ANTIBIOTIC AGENT; PTH1 DEFENSIN; SKIN POLYPEPTIDE YY; STIBOGLUCONATE SODIUM; TACHYPLESIN 1; TEMPORIN 1SA; TEMPORIN A; TEMPORIN B; UNCLASSIFIED DRUG;

AMASTIGOTE; AMIDATION; ANTIBACTERIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CLINICAL TRIAL; CYTOTOXICITY; DRUG COST; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; LEISHMANIA MAJOR; MACROPHAGE; MITOCHONDRION; PHAGOLYSOSOME; PROMASTIGOTE; PROTEIN DEGRADATION; REVIEW; SKIN LEISHMANIASIS; STRUCTURE ACTIVITY RELATION; VISCERAL LEISHMANIASIS;

ANTIMICROBIAL CATIONIC PEPTIDES; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; HUMANS; LEISHMANIA; LEISHMANIASIS;

EID: 77954995751     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Stuart K, Brun R, Croft S, Fairlamb A, Gurtler RE, McKerrow J, Reed S, Tarleton R: Kinetoplastids: Related protozoan pathogens, different diseases. J Clin Invest (2008) 118(4): 1301-1310.
2. Bern C, Maguire JH, Alvar J: Complexities of assessing the disease burden attributable to leishmaniasis. PloS Negl Trop Dis (2008) 2(10):e313.
3. Molina R, Gradoni L, Alvar J: HIV and the transmission of Leishmania. Ann Trop Med Parasitol (2003) 97(Suppl 1):29-45.
4. Croft SL, Barrett MP, Urbina JA: Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol (2005) 21(11):508-512.
5. Kedzierski L: Leishmaniasis vaccine: Where are we today? J Glob Infect Dis (2010) 2(2):177-185.
6. Croft SL, Sundar S, Fairlamb AH: Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 19(1):111-126.
7. AEterna Laboratories Inc: AEterna's subsidiary, Zentaris, to start distribution of Impavido in India. Press Release (2003): February 07.
8. Lead discovery for drugs for infectious tropical diseases - Strategic objectives: Special Programme for Research and Training in Tropical Diseases, WHO, Geneva, Switzerland (2010).
9. Naderer T, Vince JE, McConville MJ: Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host. (2004) Curr Mol Med 4(6):649-665.
10. Olivier M, Gregory DJ, Forget G: Subversion mechanisms by which Leishmania parasites can escape the host immune response: A signaling point of view. Clin Microbiol Rev (2005) 18(2):293-305.
11. de Oliveira CI, Nascimento IP, Barral A, Soto M, Barral-Netto M: Challenges and perspectives in vaccination against leishmaniasis. Parasitol Int (2009) 58(4):319-324.
12. Kedzierski L, Sakthianandeswaren A, Cutris JM, Andrews PC, Junk PC, Kedzierski K: Leishmaniasis: Current treatment and prospects for new drugs and vaccines. Curr Med Chem (2009) 16(5):599-614.
13. Croft SL, Coombs GH: Leishmaniasis - Current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol (2003) 19(11):502-508.
14. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M: Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 5(11):873-882. (Pubitemid 47578388)
15. Demicheli C, Ochoa R, da Silva JB, Falcao CA, Rossi-Bergmann B, de Melo AL, Sinisterra RD, Frezard F: Oral delivery of meglumine antimoniate-β- cyclodextrin complex for treatment of leishmaniasis. Antimicrob Agents Chemother (2004) 48(1): 100-103.
16. Sundar S: Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health (2001) 6(11):849-854.
17. Sundar S, Thakur BB, Tandon AK, Agrawal, Mishra CP, Mahapatra TM, Singh VP: Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ (1994) 308(6924):307.
18. Ephros M, Waldman E, Zilberstein D: Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob Agents Chemother (1997) 41(5): 1064-1068.
19. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A: Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: A study of 938 cases. Trans R Soc Trop Med Hyg (1999) 93(3):319-323.
20. Bray PG, Barrett MP, Ward SA, de Koning HP: Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends Parasitol (2003) 19(5):232-239.
21. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson ADM: Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ (1998) 76(1):25-32.
22. Leishmaniasis: Gilead Sciences Inc, Foster City, CA, USA (2010). www.gilead.com/visceral-leishmaniasis
23. Croft SL: Kinetoplastida: New therapeutic strategies. Parasite (2008) 15(3):522-527.
24. Davidson RN, den Boer M, Ritmeijer K: Paromomycin. Trans R Soc Trop Med Hyg (2009) 103(7):653-660.
25. Di Giorgio C, Faraut-Gambarelli F, Imbert A, Minodier P, Gasquet M, Dumon H: Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J Antimicrob Chemother (1999) 44(1):71-76.
26. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J: Oral miltefosine for Indian visceral leishmaniasis. New Eng J Med (2002) 347(22):1739-1746.
27. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K et al: Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis (2004) 38(9):1266-1272.
28. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP et al: Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 196(4):591-598. (Pubitemid 47206107)
29. Sindermann H, Engel J: Development of milteofosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg (2006) 100(Suppl 1) S17-S20.
30. Perez-Victoria FJ, Castanys S, Gamarro F: Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother (2003) 47(8):2397-2403.
31. Sundar S, Murray HW: Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ (2005) 83(5):394-395.
32. Cotter PD, Hill C, Ross RP: Bacteriocins: Developing innate immunity for food. Nat Rev Microbiol (2005) 3(10):777-788.
33. Thevissen K, Kristensen HH, Thomma BP, Cammue BP, Franois IE: Therapeutic potential of antifungal plant and insect defensins. Drug Discov Today (2007) 12(21-22):966-971.
34. Slocinska M, Marciniak P, Rosinski G: Insects antiviral and anticancer peptides: New leads for the future? Protein Pept Lett (2008) 15(6):578-585.
35. Zhang LJ, Falla TJ: Host defense peptides for use as potential therapeutics. Curr Opin Investig Drugs (2009) 10(2):164-171.
36. Fjell CD, Hancock RE, Cherkasov A: AMPer: A database and an automated discovery tool for antimicrobial peptides. Bioinformatics (2007) 23(9):1148-1155.
37. Diamond G, Beckloff N, Weinberg A, Kisich KO: The roles of antimicrobial peptides in innate host defense. Curr Pharm Des (2009) 15(21):2377-2392
38. Li M, Rigby K, Lai YP, Nair V, Peschel A, Schittek B, Otto M: Staphylococcus aureus mutant screen reveals interaction of the human antimicrobial peptide dermcidin with membrane phospholipids. Antimicrob Agents Chemother (2009) 53(10):4200-4210.
39. Marr AK, Gooderham WJ, Hancock RE: Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr Opin Pharmacol (2006) 6(5):468-472.
40. Hoskin DW, Ramamoorthy A: Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta (2008) 1778(2): 357-375.
41. Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Belec L, Hani K, Tangy F: The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology (2005) 334(2): 264-275.
42. Lupetti A, Danesi R, van't Wout JW, van Dissel JT, Senesi S, Nibbering PH: Antimicrobial peptides: Therapeutic potential for the treatment of Candida infections. Expert Opin Investig Drugs (2002) 11(2):309-318.
43. Silkin L, Hamza S, Kaufman S, Cobb SL, Vederas JC: Spermicidal bacteriocins: Lacticin 3147 and subtilosin A. Bioorg Med Chem Lett (2008) 18(1):3103-3106.
44. Rivas L, Luque-Ortega JR, Andreu D: Amphibian antimicrobial peptides and protozoa: Lessons from parasites. Biochim Biophys Acta (2009) 1788(8):1570-1581.
45. Gaidukov L, Fish A, Mor A: Analysis of membrane-binding properties of dermaseptin analogues: Relationships between binding and cytotoxicity. Biochemistry (2003) 42(44):12866-12874.
46. Hernandez C, Mor A, Dagger F, Nicolas P, Hernandez A, Benedetti EL, Dunia I: Functional and structural damage in Leishmania mexicana exposed to cationic peptide dermaseptin. Euro J Cell Biol (1992) 59(2):414-424.
47. Feder R, Dagan A, Mor A: Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J Biol Chem (2000) 275(6):4230-4238.
48. Brand GD, Leite JR, de Sà Mandel SM, Mesquita DA, Silva LP, Prates MV, Barbosa EA, Vinecky F, Martins GR, Galasso JH, Kuckelhaus SA et al: Novel dermaseptins from Phyllomedusa hypochondrialis (Amphibia). Biochem Biophys Res Commun (2006) 347(3):739-746.
49. Diaz-Achirica P, Ubach J, Guinea A, Andreu D, Rivas L: The plasma membrane of Leishmania donovani promastigotes is the main target for CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide. Biochem J (1998) 330(Pt 1):453-460.
50. Kückelhaus SA, Leite JR, Muniz-Junqueira MI, Sampaio RN, Bloch C Jr, Tosta CE: Antiplasmodial and antileishmanial activities of phylloseptin-1, an antimicrobial peptide from the skin secretion of Phyllomedusa azurea (Amphibia). Exp Parasitol (2009) 123(1):11-16.
51. Mangoni ML, Saugar JM, Dellisanti M, Barra D, Simmaco M, Rivas L: Temporins: Small antimicrobial peptides with leishmanicidal activity. J Biol Chem (2005) 280(2):984-990.
52. Abbassi F, Oury B, Blasco T, Sereno D, Bolbach G, Nicolas P, Hani K, Amiche M, Ladram A: Isolation, characterization and molecular cloning of new temporins from the skin of the North African ranid Pelophylax saharica. Peptides (2009) 29(9):1526-1533.
53. Mangoni ML, Papo N, Sauger JM, Barra D, Shai Y, Simmaco M, Rivas L: Effect of natural l- to d-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry (2006) 45(13):4266-4276.
54. Löfgren SE, Miletti LC, Steindel M, Bachre E, Barracco MA: Trypanocidal and leishmanicidal activities of different antimicrobial peptides (AMPs) isolated from aquatic animals. Exp Parasitol (2008) 118(2):197-202.
55. Vouldoukis I, Shai Y, Nicolas P, Mor A: Broad spectrum antibiotic activity of the skin-PYY. FEBS Lett (1996) 380(3):237-240.
56. Konno K, Rangel M, Oliveira JS, Dos Santos Cabrera MP, Fontana R, Hirata IY, Hide I, Nakata Y, Mori K, Kawano M, Fuchino H et al: Decoralin, a novel linear cationic α-helical peptide from the venom of the solitary eumenine wasp Oreumenes decoratus. Peptides (2007) 28(12):2320-2327.
57. Bera A, Singh S, Nagaraj R, Vaidya T: Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol Biochem Parasitol (2003) 127(1):23-25.
58. Boulanger N, Lowenberger, Volf P, Ursic R, Sigutova L, Sabatier L, Svobodova M, Beverley SM, Spath G, Brun R, Pesson B et al: Characterization of a defensin from the sand fly Phlebotomus duboscqi induced by challenge with bacteria or the protozoan parasite Leishmania major. Infect Immun (2004) 72(12):7140-7146.
59. Silva PI Jr, Daffre S, Bulet P: Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family. J Biol Chem (2002) 275(43):33464-33470.
60. Berrocal-Lobo M, Molina A, Rodriguez-Palenzuela P, Garcia-Olmeda F, Rivas L: Leishmania donovani: Thionins, plant antimicrobial peptides with leishmanicidal activity. Exp Parasitol (2009) 122(3):247-249.
61. Luque-Ortega JR, van't Hof W, Veerman EC, Sauger JM, Rivas L: Human antimicrobial peptide histatin 5 is a cell penetrating peptide targeting mitochondrial ATP synthesis in Leishmania. FASEB J (2008) 22(6):1817-1828.
62. Henchey LK, Jochim AL, Arora PS: Contemporary strategies for the stabilization of peptides in the α-helical conformation. Curr Opin Chem Biol (2008) 12(6):692-697.
63. Garner J, Harding MM: Design and synthesis of α-helical peptides and mimetics. Org Biomol Chem (2007) 5(22):3577-3585.
64. Pardakhty A, Varshosaz J, Rouholamini A: In vitro study of polyoxyethylene alkyl ether niosomes for the delivery of insulin. Int J Pharm (2007) 328(2):130-141.
65. Chicharro C, Granata C, Lozano R, Andreu D, Rivas L: N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. Antimicrob Agents Chemother (2001) 45(9):2441-2449.
66. Alberola J, Rodrguez A, Francino O, Roura X, Rivas L, Andreu D: Safety and efficacy of antimicrobial peptides against naturally acquired Leishmaniasis. Antimicrob Agents Chemother (2004) 48(2):641-643.
67. Roch P, Beschin A, Bernard E: Antiprotozoan and antiviral activities of non-cytotoxic truncated and variant analogues of mussel defensin. Evid Based Complement Alternat Med (2004) 1(2):167-174.
68. Guerrero E, Saugar JM, Matsuzaki K, Rivas L: Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob Agents Chemother (2004) 48(8):2980-2986.
69. Kustanovich I, Shalev DE, Mikhlin M, Gaidukov L, Mor A: Structural requirement for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J Biol Chem (2002) 277(19):16941-16951.
70. Kulkarni MM, McMaster WR, Kamysz E, Kamysz W, Engman DM, McGwire BS: The major surface-metalloprotease of the parasitic protozoan, Leishmania, protects against antimicrobial peptide-induced apoptotic killing. Mol Microbiol (2006) 62(5):1484-1497.
71. Yao CQ, Donelson JE, Wilson ME: The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression and function. Mol Biochem Parasitol (2003) 132(1):1-16.
72. Lang T, Goyard S, Lebastard M, Milon G: Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigoteharbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol (2005) 7(3):383-392.